This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
🎯 Background & Rationale
- Resource limitations: Standard sclerosing agents like talc and bleomycin are cost-prohibitive in resource-limited settings such as Mozambique.
- Clinical necessity: Recurrent malignant pleural effusions cause severe dyspnea, making affordable chemical pleurodesis an essential palliative intervention.
- Historical alternative: Sodium hydroxide (NaOH) was used historically as a low-cost pleural irritant, prompting this modern comparative evaluation.
👥 Study Design & Population
- Retrospective cohort: Single-center observational study comparing pleurodesis outcomes between sodium hydroxide and bleomycin from 2002 to 2013.
- Patient inclusion: 47 total patients with recurrent symptomatic pleural effusions (majority malignant, including Kaposi’s sarcoma and metastatic cancers) achieving 100% lung expansion post-thoracentesis.
- Intervention groups: 24 patients treated with bleomycin versus 23 patients treated with 0.5% sodium hydroxide via chest tube thoracostomy.
📈 Methodology & Rigor
- Data collection: Retrospective review of medical records at Maputo Central Hospital, evaluating baseline demographics, procedural complications, and radiographic success.
- Statistical approach: Frequencies and proportions compared using Fisher’s exact test with a significance threshold set at P < 0.05.
- Methodological limits: Retrospective design inherently risks selection bias, unmeasured confounding, and missing clinical records.
🔬 Key Findings [or Planned Endpoints]
- Clinical success: No statistically significant difference in complete lung expansion or clinical success rates between sodium hydroxide and bleomycin groups.
- General complications: General adverse events (fever, nausea, cough, dyspnea) occurred significantly less often with sodium hydroxide (10%) compared to bleomycin (38%, exact P value not detailed in text).
- Fever incidence: Fever was reported in 0% of the sodium hydroxide group versus 23.8% of the bleomycin group (P = 0.048).
- Recurrence rates: Only 3 patients experienced recurrent effusions requiring repeat pleurodesis, all of whom were initially treated with sodium hydroxide.
- Cost disparity: Sodium hydroxide cost approximately $0.78 per treatment versus an average of $160 per treatment for bleomycin.
⚖️ Critical Appraisal
- Internal validity: Small sample size (47 patients), non-randomized allocation, and retrospective data collection limit strong causal inferences.
- External validity: Findings are derived from a single center in a developing nation with unique malignant etiologies (e.g., high burden of Kaposi’s sarcoma), limiting global generalizability.
- Cost-effectiveness: While dramatic cost savings are evident, the lack of blinding and standardized follow-up warrants cautious interpretation of comparative efficacy.
💡 The Clinical Bottom Line
- Resource alternative: Sodium hydroxide represents an extremely low-cost, viable alternative to bleomycin for pleurodesis in resource-limited settings.
- Safety profile: Sodium hydroxide demonstrates comparable efficacy with potentially fewer general systemic side effects than bleomycin.
- Future directions: Prospective, randomized trials are needed to definitively establish the safety, optimal dosing, and long-term efficacy of sodium hydroxide pleurodesis.
Abstract
Keep reading
N opens the next oneClinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
CT-guided fiducial placement remains a relevant technique for pre-procedural localization of peripheral lung lesions.
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.